FirstEnergy Corp. vs Twist Bioscience Corp — how do they compare? FirstEnergy Corp. trades at $44.9 (market cap $25.80B), while Twist Bioscience Corp trades at $158.01 (market cap $10.32B). The key difference: FirstEnergy Corp. is far larger — about 2.5× Twist Bioscience Corp's market cap, and FirstEnergy Corp. pays a 4.17% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold FirstEnergy Corp. for 71 Days and Twist Bioscience Corp for 27 Days on average.
| FE | TWST | |
|---|---|---|
Market Cap | $25.80B | $10.32B |
Volume | 5,328,616 | 5,894,998 |
Sector | Utilities | Health |
52-Week High | $51.91 | $205.00 |
52-Week Low | $43.04 | $25.45 |
Typical Hold Time | 71 Days | 27 Days |
Enterprise Value | $54.72B | $10.24B |
Dividend Yield | 4.17% | — |
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $44.85, up 1.33% with mixed technical signals showing bullish overall but bearish moving averages. The company reported Q1 2026 EPS beat but missed Q4 2025 and Q2 2026 expectations, with Q3 2026 results pending. Revenue grew to $15.09B in 2025 with stable profit margins around 6.86%. Recent developments include the $36B Energize365 investment plan and consistent dividend payments, supporting long-term growth prospects in the utility sector.
FE presents a moderate buy opportunity with analyst consensus target of $52.80 offering 17.7% upside. Strong institutional interest and dividend stability balance execution risks from heavy capital expenditures and debt levels. The stock's valuation appears reasonable with P/E of 23.84, though investors should monitor earnings consistency and regulatory developments in the electric utility space.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →